Keywords: AstraZeneca, Seroquel, Off-label marketing, Merck & Co, Vioxx, Investors, Law suit
AstraZeneca confirms $520 million deal for US off-label marketing of Seroquel, as HHS details action; Court approves suits against Merck & Co over Vioxx
Article | 28 April 2010
Following rumors reported yesterday as a result of a Wall Street Journal article, Anglo-Swedish drug major AstraZeneca late on Tuesday ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
